Novo Nordisk signed deals to the tune of billions as part of major strategy shift
In 2018, Novo Nordisk entered agreements with a potential value of totaling DKK 16.3 billion (USD 2.5 billion). In addition, the danish drug group signed several deals with an undisclosed value. A necessary development in changing times, says analysts.
Denmark's largest drug group Novo Nordisk is in a period of change unlike anything else since the 'genesis' of the company's present form at the turn of the millennium, when the pharma-, enzyme- and investment businesses were separated between Novo Nordisk, Novozymes and Novo Holdings.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
